Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIR ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

A little-known Chinese company has made a drug that beats the world's biggest-selling medicine, said a CNN report on ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

▎药明康德内容团队编辑默沙东（MSD）今日宣布，美国FDA已接受该公司为重磅免疫疗法Keytruda递交的补充生物制品许可申请（sBLA），寻求批准Keytruda作为手术前的新辅助疗法，用于治疗可切除局部晚期头颈部鳞状细胞癌（LA-HNSCC）患者，随后联合标准放疗（有或无顺铂）作为辅助治疗，然后再作为单药进行辅助治疗。FDA同时授 ...